Cantor Fitzgerald Comments on Theratechnologies Inc.’s FY2024 Earnings (TSE:TH)

Theratechnologies Inc. (TSE:TH – Free Report) – Analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for Theratechnologies in a report issued on Tuesday, July 11th. Cantor Fitzgerald analyst L. Chen forecasts that the company will post earnings of $0.05 per share for the year. The consensus estimate for Theratechnologies’ current full-year earnings is $0.02 per share.

Get Theratechnologies alerts:

Theratechnologies (TSE:TH – Get Free Report) last released its quarterly earnings results on Wednesday, April 12th. The company reported C($0.15) earnings per share for the quarter. The company had revenue of C$26.87 million during the quarter. Theratechnologies had a negative return on equity of 1,116.86% and a negative net margin of 59.76%.

Separately, National Bankshares lowered their price target on Theratechnologies from C$3.25 to C$2.25 and set a “sector perform” rating for the company in a research report on Thursday, April 13th.

Theratechnologies Stock Performance

Theratechnologies stock opened at C$1.16 on Wednesday. The firm has a market capitalization of C$112.30 million, a P/E ratio of -1.55, a PEG ratio of -8.50 and a beta of 1.52. The stock has a fifty day moving average price of C$1.23 and a 200 day moving average price of C$1.24. Theratechnologies has a 52 week low of C$1.00 and a 52 week high of C$3.75. The company has a current ratio of 0.83, a quick ratio of 0.64 and a debt-to-equity ratio of 562.07.

Theratechnologies Company Profile

(Get Free Report)

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients.

Read More

• Five stocks we like better than Theratechnologies
• Contrarian Play: Beyond Meat Is At An Inflection Point 
• Alibaba Just Flashed Green, Very Green
• This Small Cap Stock Surged Over 100%
• The CPI Data Isn’t As Good As You Think It Is 
• How to Invest in Gold and Silver

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.